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Craniometaphyseal dysplasia (CMD) is a rare skeletal disorder characterized by progressive thickening and increased
mineral density of craniofacial bones and abnormally developed metaphyses in long bones. Linkage studies mapped
the locus for the autosomal dominant form of CMD to an ∼5-cM interval on chromosome 5p, which is defined
by recombinations between loci D5S810 and D5S1954. Mutational analysis of positional candidate genes was
performed, and we describe herein three different mutations, in five different families and in isolated cases, in ANK,
a multipass transmembrane protein involved in the transport of intracellular pyrophosphate into extracellularmatrix.
The mutations are two in-frame deletions and one in-frame insertion caused by a splicing defect. All mutations
cluster within seven amino acids in one of the six possible cytosolic domains of ANK. These results suggest that
the mutated protein has a dominant negative effect on the function of ANK, since reduced levels of pyrophosphate
in bone matrix are known to increase mineralization.
Introduction
Autosomal dominant (AD) craniometaphyseal dysplasia
(CMD [MIM 123000]) (Jackson et al. 1954) is a rare
skeletal condition that involves abnormal bone forma-
tion and mineralization in membranous as well as en-
dochondral bones. Increased density of craniofacial
bones, beginning at the base of the skull, can be diag-
nosed during early childhood. Sclerosis is accompanied
by progressive thickening of the bones, which can cause
narrowing of cranial foramina and can lead to severe
visual and neurological impairment, such as facial palsy
and deafness. Typical facial features of CMD include a
wide nasal bridge, paranasal bossing, and orbital hy-
pertelorism (fig. 1). Metaphyses of long bones are wid-
ened (Erlenmeyer flask-shaped) and exhibit decreased
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density (fig. 1). Diaphyses show normal patterns of tra-
beculation; however, the cortex can be thicker in some
instances.
Thickened cranial bones or flared metaphyses are not
unique to CMD and are seen in a number of skeletal
disorders. Many of these conditions are very rare, and
differential diagnosis can be difficult. CMD is clinically
distinct from other craniotubular disorders such as cran-
iodiaphyseal dysplasia (MIM 218300), Pyle disease
(MIM 265900), osteopathia striata with cranial scle-
rosis (MIM 166500, frontometaphyseal dysplasia
(MIM 305620), and sclerosteosis (MIM 269500). Scle-
rosteosis is the only disorder for which the causative
gene (SOST) has been identified (Balemans et al. 2001;
Brunkow et al. 2001).
CMD occurs in an AD and an autosomal recessive
(AR) form (MIM 218400) (Gorlin et al. 1969). Sclerosis
of cranial bones is usually much more severe in the rare
AR form. AR CMD has recently been mapped to a 7-
cM interval on chromosome 6q21-22 (Iughetti et al.
2000). A genetic locus for the AD form of CMD, en-
compassing 19 cM on chromosome 5p15.2-p14.1
(Nurnberg et al. 1997), has been reported for a large
pedigree of German origin. An 11-cM interval in the
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Figure 1 A and B, Proband of pedigree A, at age 12, showing
typical features of CMD—for example, hypertelorism, wide nasal
bridge, and paranasal bossing. C, Metaphyseal flaring in a 2-year-old
child from family C.
Table 1
Primers Used to Amplify ANK Exons from Genomic DNA of Individuals Affected with CMD
EXON
PRIMER
(5′r3′)
Forward Reverse
1 GATGGACTTGAGCTTGCGGATC AGAGGGACTCGGAGCAGGTGAC
2 TGCAGTGGTCAGGTATCTCCTTC GTCTTAAGCTAGGAGCACAAGCG
3 AACCCAGAGCATTCATTGGCTG GAATGTACTTCCTGCCATTAAGC
4 CTGGGCTGCTAAGGCTTTGAG CGGTGCTGGCAAAACCAGGTC
5 GTCAAGATCTTTGCTCAGAGGTC CTTGGCCTCTGGGTATGACATC
6 GCAGCTTGCCAGCTGTCTCGG GGCTTCCTAGTGTGACTGTCATG
7 CTGTCCTCAGTGGCTGCACC AGGGAAGCAGGACTGAGAAGC
8 CCGCCTGGCAAACTGTCACTTG GAAGAGATTGCTAATTAATCCAGCATC
9 CATGCCCACCACCCAGTCAG GCATCTTTCTAAGCCACAGTG
10 CAGCGGCTCAACAGCAAGGC GGATCCCAAGAGCCTCCACCTG
11 GAAGCCAGCAGATGGAGAACG CACCCTAAGCCACGAGACTGG
12 GCTAAGATGCAAAAGAGGTGACG CAACAGTAAAGACCATTCACTAGG
same locus has been determined for a South African
kindred (J. Gardner, P. Beighton, H. Hamersma, S. Sel-
lars, and R. Ramesar, unpublished data).
We have independently mapped CMD to the 5p locus
and have defined a 5-cM interval by means of linkage
studies and haplotype analysis. Mutational analysis of
candidate genes within this locus revealed sequence var-
iants in the transmembrane protein ANK. Herein we
show that mutations in ANK cause CMD in several
sporadic cases and in families with AD inheritance of
CMD.
Subjects and Methods
Subjects
Familial and sporadic cases of CMDwere contributed
by clinical collaborators (D.K.G., P.B., J.G., H.H., S.S.,
R.R., A.S., A.C.L., A.S., R.J.G., C.R.A., and J.B.M.) in
accordance with the regulations of their institutional re-
view boards and the Institutional Review Board of Har-
vard Medical School. Participating subjects were eval-
uated clinically, and peripheral blood samples were
obtained.
Genomewide Screening and Physical Map
DNA isolation, genomewide screening, and linkage
analysis were performed as described elsewhere (Tiziani
et al. 1999). Information about additional markers and
physical clones was obtained from the literature (Church
et al. 1997), the Lawrence Berkeley National Laboratory
Sequence Archive, the Genome Database, GenBank, and
the Celera database. New microsatellite markers were
developed by cycle sequencing of (CA)n microsatellites
from the genomic clones directly, using degenerate (GT)8
primers (Hawkins et al. 1994). BAC and PAC clones
were obtained from BACPAC Resources.
Mutation Analysis
Exons of candidate genes were amplified with primers
in flanking intron sequences, using genomic DNA of
affected individuals. Intronic sequences were available
in either GenBank (accession numbers AC010491 and
AC026437) or the Celera Discovery System (CeleraGen-
omics; accession number GA_65585516). Primers used
to amplify ANK exons are given in table 1. PCR prod-
ucts were purified with a Qiagen PCR purification kit
and genomic clones with a Qiagen Midiprep kit. PCR-
generated templates were sequenced from both ends on
an ABI 3100 capillary sequencer with ABI Big Dye chem-
istry or manually with a Thermo Sequenase radiolabeled
terminator cycle-sequencing kit (USB). Alternatively,
cDNA was reverse-transcribed (Omniscript RT kit,
Qiagen) from RNA of Epstein-Barr virus (EBV)–trans-
formed patient lymphoblasts and used for PCR ampli-
fication with exonic primers (Chan and Cole 1991). The
products were sequenced and searched for heterozygous
sequence variations or splicing variants. PCR-amplified
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Figure 2 Pedigree of family A shows haplotypes for selected markers in the CMD locus on chromosome 5p, defining an initial 30-cM
disease-gene interval. Recombinations in family C reduced the size of the locus to 5 cM, with breakpoints between markers D5S810 (telomeric)
and D5S1954 (centromeric). The most likely haplotypes for the linked allele are boxed.
Figure 3 Electropherograms of partial sequences of ANK show-
ing deletions and an insertion in families with CMD. Sequence vari-
ations are indicated by arrows (f). Capital letters next to electro-
pherograms indicate wild-type sequence (WT) and families and
sporadic cases for which the respective mutation was tested. Electro-
pherograms for families C, F and D, S show the sequence of the disease
allele after clonal selection of PCR fragments from ANK exon 9 am-
plified from genomic DNA. The electropherograms for family G show
wild-type (WT) and mutant allele carrying the insertion from cDNA
after clonal selection, and the heterozygous ArG transition in intron
9 from genomic DNA.
products containing putative mutations were cloned into
PCRII-TOPO TA cloning vectors (Invitrogen) for clonal
selection, and several clones for each mutation were se-
quenced. Variations in patient and wild-type sequences
were examined, using BLAST. Electropherograms were
examined visually for heterozygosities.
ANK Expression
cDNA was prepared with an Omniscript RT kit (Qia-
gen), and fragments were amplified using Hotstart Taq
polymerase (Qiagen). A 716-nt fragment of ANK was
amplified with primers ANK820up (5′-gtggcgattttgacag-
ccacatac-3′) and ANK12dw (5′-gatgccgaagtgtcatcctga-
ctg-3′) in 40 cycles (94C for 30 s, 58C for 30 s, and
72C for 1 min) after a 15-min initial denaturation at
95C. A 553-nt GAPDH fragment was amplified with
primers G3PDH-F (5′-gaccacagtccatgccatcact-3′) and
G3PDH-R (5′-tccaccaccctgttgctgtag-3′) in 30 cycles
(94C for 30 s, 58C for 30 s, and 72C for 2 min) after
a 15-min initial denaturation at 95C.
Results
For this study, we recruited five families (families A, B,
C, G, and F) with AD inheritance of CMD and five
families (families D, E, X1, X2, and S) with sporadic
cases of CMD. Families A, B, C, G, and F include a total
of 64 participating members, 37 of them affected with
CMD; 23 (62%) of these affected individuals are female
and 14 (38%) are male. The female:male ratio for all
affected members of the families is similar, namely 59:
41. The transmission of the CMD phenotype is complete
in all families, but the expressivity varies. Some individ-
uals are severely affected, whereas others show onlymild
expression of the disease. There is no evidence for an-
ticipation, although there are some children who needed
surgical intervention, early in childhood, to decompress
facial nerve canals.
In the course of a genomewide screen, we initially
identified a 30-cM locus between markers D5S2088 and
D5S502 for family A (fig. 2) (Dib et al. 1996) (National
Center for Biotechnology Information [NCBI] Map
Viewer). Family B (data not shown) colocalized and
showed no recombination within this region. This locus
is confirmed by independent data from other groups,
who mapped the AD CMD locus to a 19-cM region
(Nurnberg et al. 1997) and an 11-cM region (J. Gardner,
P. Beighton, H. Hamersma, S. Sellars, and R. Ramesar,
unpublished data) within this interval. With family C
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Figure 4 Locations of ANK mutations in patients with CMD
(model of ANK according to Ho et al. 2000). The mutations cluster
in a cytoplasmic domain between two putative transmembrane do-
mains (mutations are indicated by arrows [r]).
Figure 5 Exon-intron boundaries of ANK exons 9 and 10. Cap-
ital letters indicate exon sequences; lowercase letters indicate intron
sequences. Three nucleotides on the splice-acceptor site of intron 9,
which are retained in the cDNA sequence of family G, are marked in
boldface type. Exon 9 ends with a split codon, which contributes to
the codon (GCA) for the extra alanine. The new splice-acceptor site
in the disease allele is created by the heterozygous point mutation
(arg) in position 4 of the splice-donor site of intron 9 (marked by
an arrow (f).
(fig. 2), we were then able to restrict the locus to an
interval between D5S810 and D5S1954, which corre-
sponds to a physical size of 2–3Mb (Church et al. 1997;
R. Shiang, unpublished data) or to ∼5 cM, according
to the NCBI Map Viewer. To increase the resolution of
the interval, we identified several new microsatellite re-
peats on BAC and PAC clones. Sequencing of the ge-
nomic clones with degenerate N(GT)8 primers (Haw-
kins et al. 1994) resulted in a number of new
dinucleotide-repeat markers. New repeat markers rel-
evant for fine mapping were 143i2-11 (143i2-11UP:
5′-GAGGCAGGAGAATGCCTGAGCC-3′ and 143i2-
11DW: 5′-CCACCGCACACTACTGACCAAAAC-3′),
143i2-12 (143i2-12UP: 5′-GCCAGGCATGGTAGTG-
TGCGTC-3′ and 143i2-12DW: 5′-GCATGTGTCTCC-
CATTGGCGTT-3′). Tight linkage for family C was
found between D5S2081 (LOD score 3.4) and 143i2-
12 (LOD score 3.9).
The CMD interval contains only two fully described
genes but numerous expressed sequence tags. TRIO
(Debant et al. 1996), which is implicated in actin po-
lymerization, was considered an obvious candidate gene
because of its possible function during actin reorgani-
zation in osteoclasts, but it was excluded by direct se-
quencing of genomic and cDNA fragments. Another
candidate, ANK, was recently assigned to chromosome
5p (Ho et al. 2000). We screened a panel of individuals
affected with CMD for nucleic acid changes in ANK by
direct sequencing of genomic ANK PCR products (for-
ward and reverse). We found two in-frame deletions for
families C, F, D, and S in exon 9, and we detected one
in-frame insertion in exon 10 for family G (fig. 3). All
deletions and the insertion found are located within
seven amino acids in the cytosolic domain between
transmembrane domains 8 and 9 (fig. 4). The deletions
of three nucleotides in exon 9 (TCT1127–1129 in AD fam-
ilies C and F and CTC1122–1124 in the sporadic cases D
and S) result in the deletion of Phe376 and Ser375 , re-
spectively (table 2). By direct sequencing of cDNAprod-
ucts from affected members of the AD family G, we
detected the insertion of an extra alanine between Pro380
and Val381 (fig. 5). Direct sequencing of a genomic PCR
fragment of exon 10 revealed a heterozygous nucleotide
change (arg) at position 4 at the splice-acceptor site
of intron 9. The arg transition produces a novel splice-
acceptor site, which leads to the retention of three bases
(cag) in the cDNA sequence. Exon 9 ends with a split
codon (G), which contributes to the codon (GCA) for
alanine. Testing on the genomic level showed that the
mutation cosegregates in family G. We also tested
cDNA from four affected and four unaffected members
of family G and found cosegregation of the phenotype
at the cDNA level. None of the sequence variants have
been found in a panel of 80 unaffected control
individuals.
By reverse transcriptase (RT)–PCR, we show that the
mRNA for ANK is expressed in normal osteoblasts (fig.
6) from mandibular bone and from iliac bone, which
have been kept in primary cell culture for three passages.
The mRNA could not be detected in cultured osteo-
clastic cells from human osteoclastoma, which had been
highly purified with the 23c6 anti–vitronectin-receptor
antibody (a gift from G. D. Roodman).
Discussion
In this study, we describe the identification of mutations
in ANK, which can cause CMD in families with AD
CMD and in sporadic cases. The ANK gene encodes a
492–amino acid multipass transmembrane protein with
10 potential transmembrane domains.
All mutations described here are located in a cytosolic
domain 4–10 amino acid residues C-terminal of the
eighth transmembrane domain and 23–29 amino acid
residues N-terminal of the ninth transmembrane do-
main. The mutations consist of two different in-frame
single–amino acid deletions and one in-frame insertion
of a single amino acid. The deletions were detected by
direct sequencing of genomic fragments (families C, F,
D, and S) as well as by sequencing cDNA from EBV-
transformed lymphoblasts (families C, D, and S). The
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Table 2
Mutations in ANK That Cause CMD
Mutation Change
Family or
Families
Deletion:
TCT1127–1129 DPhe376 C and F
CTC1122–1124 DSer375 D and S
Insertion:
CAG1139–1141 Ala380 G
Figure 6 Upper panel, Expression of ANK by RT-PCR from
cultured osteoblasts from mandibular (lane 1) and iliac (lane 2) bone,
and from osteoclasts from osteoclastoma (lane 3). Lower panel,
GAPDH fragments were amplified as internal controls.
insertion of a single alanine was detected in cDNA of
family G, but the mutation itself is a point mutation
(arg transition) in the splice-acceptor site of intron 9.
This leads to the creation of a cryptic splice site and to
the retention of three nucleotides in exon 10. We are
confident that the described sequence variants are mu-
tations (1) because of the accumulation of three differ-
ent variants in the same domain of ANK in individuals
with CMD, (2) because all the variants cosegregated
with the phenotype in the respective families, and (3)
because these variants were not found in parents or
siblings of the individuals representing sporadic cases.
None of the deletions were found in a panel of 80 un-
affected control individuals. Interestingly, no mutations
have been found either in families A and B or in the
sporadic cases X1, X2, and E, despite thorough se-
quencing of genomic DNA and sequencing of cDNA
from two affected individuals in pedigree A. Since fam-
ilies A and B were initially used to map the CMD locus
in our laboratory, we think it is possible that CMD in
these two families is caused by mutations in cis-acting
regulatory elements, such as in the promoter or en-
hancer/silencer regions of ANK. In this case, compro-
mised expression of ANK could result in haploinsuffi-
ciency. We cannot, at this point, exclude positional
effects (Kleinjan and van Heyningen 1998), which can
be caused by chromosomal rearrangement outside the
transcription and promoter regions. Finally, it is pos-
sible that there is genetic heterogeneity, especially for
the sporadic cases X1, X2, and E. A distinct locus for
AR CMD (Iughetti et al. 2000) has already been de-
scribed on chromosome 6q21-22.
Expression of mouse ank has been found in articular
cartilage and in many nonskeletal tissues (Ho et al.
2000). We showed by RT-PCR that the mRNA is ex-
pressed in osteoblasts from primary cell culture but was
not detected in cultured osteoclastic cells from human
osteoclastoma, which had been highly purified with the
23c6 anti–vitronectin-receptor antibody (fig. 6). ANK
is likely to be a multipass transmembrane protein, and
functional studies suggest that ANK is involved in trans-
port or cotransport of intracellular pyrophosphate (PPi)
into extracellular matrix (Ho et al. 2000).
A nonsense mutation in mouse ank results in a pre-
mature stop codon. In homozygous mice, the expression
of the ank protein is ablated or at least reduced below
detectable levels (Ho et al. 2000). Overexpression of the
murine ank mutation in cultured cells results in in-
creased intracellular and decreased extracellular PPi
concentration. Skeletal pyrophosphate levels are critical
for regulation of mineralization in bone. Increased ex-
tracellular PPi concentrations, such as in hypophospha-
tasia (tissue-nonspecific alkaline phosphatase [MIM
146300]) (Caswell et al. 1991), have a negative effect
on bone mineralization; thus, decreased levels of extra-
cellular PPi in bone may result in increased bone density.
Therefore, it is likely that mutations in ANK of patients
with CMD lead to decreased PPi levels in bone extra-
cellular matrix, which in turn cause increased density
and progressive thickening of cranial bones. It may well
be the change in mineral content that prevents osteo-
clasts from remodeling cranial bone at a normal rate.
Homozygous ank/ank mutant mice develop progres-
sive generalized ankylosis of joints (Sweet and Green
1981), whereas heterozygous mice show no detectable
phenotype. Although the murine ank mutation results
in a loss of function, the mutations found in CMD pa-
tients are likely to have a dominant negative effect on
the function of ANK. However, if future research shows
that mutations in cis-acting regulatory elements can also
lead to CMD in humans, reduced ANK expression
would also have to be considered as a cause for CMD.
It is possible that there is a dose effect of ANK expres-
sion in humans, resulting in CMD, although hetero-
zygous ank mice do not have a detectable phenotype.
The radiolucent, flared metaphyses in CMD patients
are likely to be the result of a remodeling defect. Hy-
pertrophic cartilage in normal epiphyseal growth plates
is calcified before it is degraded and primary bone is
formed. Decreased levels of PPi in hypertrophic cartilage
of patients with CMD may affect calcification, normal
cartilage degradation, and osteoid deposition, which in
the end affects proper trabeculation of the metaphyses.
All the mutations found to date localize to a putative
cytosolic domain of ANK and are either an insertion or
a deletion of one amino acid. Therefore, it is conceivable
that this domain is critically involved in complex for-
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mation with another protein or in interaction with py-
rophosphate or another small molecule involved in py-
rophosphate transport, although no similarity to known
domains has been found so far. CMD mutations provide
a good genetic model to study the regulation of bone
mineralization by inorganic phosphate and the precise
role of ANK in PPi transport mechanisms. These studies
may, in the future, benefit not only patients with CMD
but also patients with deficiencies in skeletal miner-
alization.
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